Eisai and Biogen said on September 24 that Australian regulators have approved the Alzheimer’s therapy Leqembi (lecanemab), reversing their earlier rejection following a tribunal review. The launch is set for April-September 2026, according to the Japanese pharma. The Therapeutic Goods…
To read the full story
Related Article
- Australia Rejects Lecanemab Again, Eisai to Challenge Decision
March 4, 2025
- Eisai Alzheimer’s Drug Hits Another Snag, This Time in Australia
October 17, 2024
BUSINESS
- Lunsumio Combo Hits PIII Goal in Follicular Lymphoma: Roche
September 18, 2026
- Padcev-Keytruda Gets CHMP Nod for Expanded MIBC Use
September 18, 2026
- SanBio Eyes October Start for Akuugo Treatment
September 18, 2026
- Toho Unit to Launch Pharma-Wholesaler Payment Service
September 18, 2026
- Astellas Names Marino General Counsel, Compliance Chief
September 18, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…





